Liquidia Corporation
LQDA
Rank in Stocks
#4682
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Share Price
$36.17
Market Cap
$3.24B
Change (1 day)
5.98%
Change (1 year)
48.00%
Country
US
Trade Liquidia Corporation (LQDA)
Category
Healthcare
Revenue for Liquidia Corporation (LQDA)
Revenue in Jun 2026 TTM: $450.91M
According to Liquidia Corporation latest financial reports the company's current revenue (TTM) is $450.91M. In 2023 the company made a revenue of $17.49M an increase over the revenue in the year 2022 that was $15.94M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Liquidia Corporation from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $450.91M | 3,121.68% |
| 2024 | $14.00M | -19.97% |
| 2023 | $17.49M | 9.75% |
| 2022 | $15.94M | 23.98% |
| 2021 | $12.85M | 1,637.77% |
| 2020 | $739.63K | -90.84% |
| 2019 | $8.07M | 198.20% |
| 2018 | $2.71M | -62.70% |
| 2017 | $7.26M | -45.08% |
| 2016 | $13.22M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $2.54B | 462.42% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | 84.25% |
US
|
